GoodRx has made the newly FDA‑approved Wegovy® oral semaglutide pill available for cash payment at a starting price of $149 per month, with the drug now accessible at more than 70,000 pharmacies nationwide.
The $149/month price applies to the 1.5 mg and 4 mg starting doses; the 4 mg dose will rise to $199 after April 15 2026, while the 9 mg and 25 mg doses are priced at $299 per month. This tiered pricing strategy gives cash‑paying patients a clear, low‑cost entry point while still allowing higher‑dose options for those who need them.
The oral Wegovy pill received FDA approval on December 22 2025, and GoodRx’s Pharma Manufacturer Solutions revenue grew 54% year‑over‑year to $43.4 million in Q3 2025, up from $28.1 million in Q3 2024. The launch is a key driver of that growth, adding a high‑margin, high‑demand obesity drug to GoodRx’s direct‑to‑patient portfolio.
GoodRx’s strategy has shifted from a focus on consumer discount cards to monetizing manufacturer relationships. By partnering with Novo Nordisk, the company can capture a share of the expanding weight‑loss market and provide a transparent cash price that bypasses insurance complexities. The launch also dovetails with GoodRx’s “GoodRx for Weight Loss” platform, which connects patients to licensed providers and streamlines the prescription process.
The weight‑loss drug market is highly competitive. Eli Lilly’s Zepbound and other direct‑to‑consumer platforms such as Hims & Hers, LifeMD, and Ro also offer GLP‑1 medications. GoodRx’s previous collaboration with Novo Nordisk in August 2025, which offered Ozempic and Wegovy pens for $499/month, demonstrated the company’s ability to secure attractive pricing agreements and expand access to high‑demand drugs.
Wendy Barnes, President and CEO of GoodRx, said the company is uniquely positioned to help patients navigate treatment choices. She highlighted the combination of transparent cash pricing, streamlined access to care, and broad pharmacy availability as a “simpler, more consumer‑friendly” approach to weight‑management treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.